Weiwei Ma

Statistics

Publications

Citations

121

H-Index

Active since

2014

Affiliations

Tianjin Medical University Cancer Institute and Hospital(Current)

Weiwei Ma is an author at Tianjin Medical University Cancer Institute and Hospital specializing in sorafenib therapy, adjuvant therapy, and hepatocellular carcinoma treatment.

ORCID

Publications per year

2014–2019

Publications

Metabolomics analysis of serum from subjects after occupational exposure to acrylamide using UPLC-MS

Shengyuan Wang, Cuiping Yu, Yu-Lin Pan et al. · Molecular and Cellular Endocrinology · 2017 · 67 citations

Life Sciences, Toxicology, Analytical Toxicology +13

Adjuvant sorafenib reduced mortality and prolonged overall survival and post-recurrence survival in hepatocellular carcinoma patients after curative resection: A single-center experience

Wei Zhang, Gang Zhao, Kai Wei et al. · BioScience Trends · 2014 · 33 citations · Full text

Medicine, Oncology, Surgery +16

Efficacy of intestinal obstruction stent combined with laparoscopic surgery and neoadjuvant chemotherapy in patients with obstructive colorectal cancer

Leilei Yang, Weiwei Ma, Meizhen Wang et al. · Oncology Letters · 2019 · 11 citations · Full text

Medicine, Oncology, Surgery +17

Adjuvant sorafenib therapy in patients with resected hepatocellular carcinoma: evaluation of predictive factors

Wei Zhang, Gang Zhao, Kai Wei et al. · Medical Oncology · 2015 · 10 citations

Medicine, Oncology, Oncologic Surgery +11

1–4 of 4